<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of hypomethylating agent therapy (<z:chebi fb="1" ids="6824">HMT</z:chebi>) as a bridge to allogeneic hematopoietic cell transplantation (alloHCT) in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) remains undetermined </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the feasibility of <z:chebi fb="1" ids="6824">HMT</z:chebi> followed by alloHCT in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 19 patients who received <z:chebi fb="1" ids="6824">HMT</z:chebi> followed by alloHCT were analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 7 patients were classified as low-risk and 12 as high-risk, based on World Health Organization (WHO) classification at the time of <z:chebi fb="1" ids="6824">HMT</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="1" ids="6824">HMT</z:chebi> consisted of <z:chebi fb="0" ids="50131">decitabine</z:chebi> in 9 patients and <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in 10 </plain></SENT>
<SENT sid="5" pm="."><plain>After <z:chebi fb="1" ids="6824">HMT</z:chebi>, two patients achieved CR, six mCR, three hematologic improvement alone, and six SD in terms of best response </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="1" ids="6824">HMT</z:chebi> did not alter WHO classification in 15 patients (79%), whereas 1 patient (5%) improved and 3 (16%) progressed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Most patients (95%) received a non-myeloablative conditioning regimen based on fludarabine/BU/anti-thymocyte globulin, and peripheral blood-mobilized stem cells </plain></SENT>
<SENT sid="8" pm="."><plain>Neutrophil and platelet engraftments were achieved in 95 and 79% of patients, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>The incidences of <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD were 42 and 26%, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 2-year OS rates were 68%, and the overall outcomes of those who achieved CR/mCR with <z:chebi fb="1" ids="6824">HMT</z:chebi> tended to be superior to those without CR/mCR </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="1" ids="6824">HMT</z:chebi> followed by alloHCT was a feasible and effective treatment strategy for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>